Cart
sales@molnova.com
Lodelcizumab
CAS No. 1355338-54-3
Lodelcizumab( —— )
Catalog No. M37308 CAS No. 1355338-54-3
Lodelcizumab (LGT 209) is a monoclonal antibody targeting the preprotein convertase Bacillus subtilis protease Kexin-9 (PCSK9) and is used to study hypercholesterolemia.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1169 | In Stock |
|
| 10MG | 1891 | In Stock |
|
| 25MG | 2803 | In Stock |
|
| 50MG | 3701 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLodelcizumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLodelcizumab (LGT 209) is a monoclonal antibody targeting the preprotein convertase Bacillus subtilis protease Kexin-9 (PCSK9) and is used to study hypercholesterolemia.
-
DescriptionLodelcizumab is a monoclonal antibody. Lodelcizumab can be used for the research of hypercholesterolemia.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1355338-54-3
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Pordy, et al. Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis. Patent. WO2017031151 A1.
molnova catalog
related products
-
gp100 (476-485)
gp100 (476-485)
-
TL4-12
TL4-12 is a specific MAP4K2/GCK inhibitor that inhibits IKZF1 and BCL-6.TL4-12 inhibits MM cell proliferation and induces apoptosis, and can be used in the study of multiple myeloma (MM).
-
RS5517
RS5517 is a novel PDZ1 structural domain ligand for the study of colorectal cancer.
